According to a new study published in Cancer, an annual screening mammogram starting at age 40 has the greatest impact on reducing mortality.
The conflict over the recommended age for a screening mammogram continues with a new study whose authors conclude that an annual screening starting at age 40 has the greatest impact on reducing mortality.
The study used mean values from 6 Cancer Intervention and Surveillance Modeling Network (CISNET) models to compare 3 recommendations from major healthcare organizations:
Per their analysis, the highest reduction in mortality was observed in the cohort that started annual screening at age 40 and continued until age 84 years (mean reduction, 39.6%). The second-highest mortality reduction was observed in the hybrid group (mean reduction 30.8%)—this group initiated their annual screening at age 45 and continued until age 54, followed by biennial screening from 55 to 79. The group that followed the biennial screening recommendation between 50 to 74 years had the lowest reduction in mortality (23.2%).
The analysis showed that for a single-year cohort of women aged 40 years, an annual screening mammogram initiated at age 40 would prevent 29,369 deaths. This compared with 22,829 lives saved for the hybrid screening and 15,599 lives for the biennial screening ages 50 to 74 years (based on 2016 CISNET estimates).
“Our findings are important and novel because this is the first time the 3 most widely discussed recommendations for screening mammography have been compared head to head,” senior author Elizabeth Kagan Arleo, MD, of Weill Cornell Medicine, said in a statement. “Our research would be put to good use if, because of our findings, women chose to start annual screening mammography starting at age 40. Over the long term, this would be significant because fewer women would die from breast cancer.”
Arleo would like women and their physicians to use the findings of this analysis to guide screening choices, with respect to initiation and frequency of screening.
Otis Brawley, MD, FACP, chief medical officer of the American Cancer Society, wrote in an accompanying editorial highlighted the importance on an individual’s value judgement.
“Our goal should be to provide truthful, balanced information so that women can make informed choices about when to start screening for breast cancer. A woman who is making a decision about screening is more interested in her personal chances of benefit and risk of harm and is less interested in the benefits to the population,” he wrote.
His editorial also pointed out the limitations of a mammogram and emphasized the importance of a better test for women that would avoid false positives and be more sensitive.
Reference
Arleo EK, Hendrick R, Helvie MA, and Sickles EA. Comparison of recommendations for screening mammography using CISNET models [published online August 21, 2017]. Cancer. 2017. doi: 10.1002/cncr.30842.
Government agencies have created an online portal for the public to report potential anticompetitive practices in health care; there are changes coming to the “boxed warning” section for chimeric antigen receptor T-cell therapies (CAR T) to highlight T-cell blood cancer risk; questions about the safety of obesity medications during pregnancy have arisen in women on them who previously struggled with fertility issues.
Read More
Gene, Light Therapy Combo Shows Promise Against Prostate Cancer Cells in Proof-of-Concept Study
April 18th 2024In their preclinical model, the researchers found efficacy both in vitro and in vivo by using CRISPR-Cas9 to mimic porphyria and combining the technology with light therapy.
Read More
Oncology Onward: A Conversation With Penn Medicine's Dr Justin Bekelman
December 19th 2023Justin Bekelman, MD, director of the Penn Center for Cancer Care Innovation, sat with our hosts Emeline Aviki, MD, MBA, and Stephen Schleicher, MD, MBA, for our final episode of 2023 to discuss the importance of collaboration between academic medicine and community oncology and testing innovative cancer care delivery in these settings.
Listen
Many Patients With Psoriasis in Clinical Trials Experience Nocebo Effects, Study Finds
April 18th 2024Half of patients exposed to placebo in clinical trials experienced adverse events (AEs), which may be partially explainable by nocebo effects, according to a recent review and meta-analysis.
Read More